Report Scope:
The scope of the study includes the major microbiome-based drugs and diagnostics that are likely to be commercialized within the next eight years. Each product within each market is analyzed to determine its market status, market potential during the time period of 2018 to 2024. Microbiome intellectual property, investments and collaborations are discussed.
Influencing factors, industry structure, challenges facing the industry and patent status are discussed. BCC Research examines companies in the industry, corporate alliances and assay consumption by indication. We profile 25+ companies participating in this rapidly developing and evolving sector.
Report Includes:
- An overview of the global markets for human microbiome-based drugs and diagnostics.
- Analyses of global market trends, with estimates from 2017, and projections of compound annual growth rates (CAGRs) through 2024.
- Coverage of areas and applications where these technologies are applicable, such as cancer, diabetes, allergic disorders, irritable bowel disorders, celiac disease, and other G.I. disorders.
- An in-depth look at macro-level trends affecting this sector.
- Market intelligence on the technologies and platforms currently being deployed to develop these drugs and diagnostics.
- Specific emphasis on the products in development for various diseases, including the specific forecasts for these products by disease and geography.
- A look at the current level of investments in the sector, intellectual property development, and future of this sector.
Human Microbiome-based Drugs and Diagnostics: Global Markets
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Intended Audience
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related Bcc Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Microbiome Overview
Scientific Background
Human Microbiome In Health and Disease
Advances In Microbiome Research
Focus Areas for Microbiome-Based Drugs and Diagnostics
Microbiome-Based Drugs: Product Development Strategies
Current Challenges In Microbiome Drug Development
Human Microbiome Project
Metahit Consortium
Public Sector Initiatives In Microbiome Research
Key Goals of the Human Microbiome Project
Key Achievements of the Human Microbiome Project
Key Goals of Metahit Initiative
Chapter 4 Human Microbiome-Based Drugs Market
Cancer
Obesity
Type 2 Diabetes
Ulcerative Colitis and Crohn's Disease
Clostridium Difficle Infection
Lactose Intolerance
Dental Caries
Recurrent Bacterial Vaginosis and Urinary Tract Infection
Skin Diseases
Hyperoxaluria
Urea Cycle Disorder
Celiac Disease
Phenylketonuria
Non-Alcoholic Steatohepatitis (Nash)
Background
Microbiome and Cancer
Microbiome-Based Drugs for Cancer: Review of Drugs In Development
Market for Microbiome-Based Drugs for Cancer
Background
Microbiome and Obesity
Microbiome-Based Drugs for Obesity: Review of Drugs In Development
Market for Microbiome-Based Drugs for Obesity
Background
Microbiome and Type 2 Diabetes
Microbiome-Based Drugs In Type 2 Diabetes: Review of Drugs In Development
Market for Microbiome-Based Drugs for Type 2 Diabetes
Background
Microbiome and Ulcerative Colitis/Crohn's Disease
Microbiome-Based Drugs for Ulcerative Colitis and Crohn's Disease: Review of Drugs In Development
Market for Microbiome-Based Products for Ulcerative Colitis and Crohn's Disease
Background
Microbiome and Clostridium Difficle Infection
Microbiome-Based Drugs for Clostridium Difficle Infection: Review of Drugs In Development
Market for Microbiome-Based Drugs for Clostridium Difficle Infection
Background
Microbiome and Lactose Intolerance
Microbiome-Based Drugs for Lactose Intolerance: Review of Drugs In Development
Market for Microbiome-Based Product for Lactose Intolerance
Background
Microbiome and Dental Caries
Microbiome-Based Drugs for Dental Caries Review of Drugs In Development
Market for Microbiome-Based Products for Dental Caries
Background
Microbiome and Recurrent Bacterial Vaginosis and Urinary Tract Infection
Microbiome-Based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection: Drugs In Development
Market for Microbiome-Based Products for Recurrent Bacterial Vaginosis and Uti
Background
Microbiome and Skin Diseases
Microbiome-Based Drugs for Skin Diseases: Review of Drugs In Development
Market for Microbiome-Based Drugs for Skin Diseases
Background
Microbiome and Hyperoxaluria
Microbiome-Based Drugs for Hyperoxaluria: Review of Drugs In Development
Market for Microbiome-Based Products for Hyperoxaluria
Background
Microbiome and Urea Cycle Disorder
Microbiome-Based Drugs for Urea Cycle Disorder: Review of Drugs In Development
Market for Microbiome-Based Drugs for Urea Cycle Disorder
Background
Microbiome and Celiac Disease
Microbiome-Based Drugs for Celiac Disease: Review of Drugs In Development
Market for Microbiome-Based Products for Celiac Disease
Background
Microbiome and Phenylketonuria
Microbiome-Based Drugs for Phenylketonuria: Review of Drugs In Development
Market for Microbiome-Based Products for Phenylketonuria
Background
Microbiome and Non-Alcoholic Steatohepatitis
Microbiome-Based Drugs for Non-Alcoholic Steatohepatitis: Review of Drugs In Development
Market for Microbiome-Based Products for Non-Alcoholic Steatohepatitis
Microbiome-Based Products for Hepatic Encephalopathy
Microbiome and Hepatic Encephalopathy
Microbiome-Based Drugs for Hepatic Encephalopathy: Review of Drugs In Development
Market for Microbiome-Based Drugs for Hepatic Encephalopathy
Drug Development Strategies
Microbiome-Based Drugs As Immune System Activators
Microbiome-Based Drugs As An Add-On To Immuno-Oncology Drugs
Microbiome-Based Drugs As Probiotic Mixtures
Microbiome-Based Drugs As Chemotherapy Adjuncts
Microbiome-Based Drugs In Development for Cancer
Micabodies (Avidbiotics)
Oncobiotics (Evelo Biosciences)
Ser-155 (Seres therapeutics)
Symberix Compound (Symberix)
Mrx581 (4d Pharma)
Ag-013 (Intrexon)
Microbial Mechanism of Disease In Obesity
Microbiota Associated With Obesity
Drug Development Strategies
Drugs In Development for Obesity
Nm-504 (Microbiome therapeutics)
Nm-313 (Microbiome therapeutics)
Fecal Microbiota Transplant (Seres therapeutics)
Drug Development Strategies
Drugs In Development
Nm-504 (Microbiome therapeutics)
Bovin Colostrum (Immuron)
Cp-001 (Caelus Health)
Seres Diabetes Program (Seres therapeutics)
Microbiota Associated With Ulcerative Colitis and Crohn's Disease
Drugs In Development
Eb-80818 (Enterome Biosciences)
Eb-110 (Enterome Biosciences)
Eb-120 (Enterome Biosciences)
Ser-287 (Seres therapeutics)
Sgm-019 (Second Genome)
Vt-301 (Vithera Pharmaceuticals)
Rbx-8225 (Rebiotix)
Ag-014 (Intrexon)
Market for Microbiome-Based Drugs for Ulcerative Colitis
Market for Microbiome-Based Drugs for Crohn's Disease
Drug Development Strategies
Drugs In Development
Ve-202 (Vedanta Biosciences)
Syn-004 (Synthetic Biologics)
Ser-262/Ser-109 (Seres therapeutics)
Avidocin Proteins (Avidbiotics)
Dav-132 (Da Volterra)
Cbm-588 (Osel Inc.)
Rbx-2660 (Rebiotix)
Drug Development Strategies
Drugs In Development
Rp-G28 (Ritter Pharmaceuticals)
Drug Development Strategies
Drugs In Development
C16-G2 (C3 Jian Inc.)
Drug Development Strategies
Drugs In Development
Acne
Rosacea
Atopic Dermatitis
Acne
Atopic Dermatitis
Rosacea
Drug Development Strategies
Drugs In Development
B-244 (Aobiome)
Drug Development Strategies
Drugs In Development
Drug Development Strategies
Drugs In Development
Drug Development Strategies
Drugs In Development
Drug Development Strategies
Drugs In Development
Drug Development Strategies
Drugs In Development
Background
Drug Development Strategies
Drugs In Development
Chapter 5 Human Microbiome-Based Diagnostics Market
Microbiome Diagnostics: Overview
Microbiome Diagnostics: Technologies
Microbiome Diagnostics: Applications
Microbiome Diagnostics: Industry Collaborations
Market for Microbiome Diagnostics
Microbiome-Based Diagnostics for Ulcerative Colitis and Crohn's Disease
Microbiome-Based Diagnostics for Cancer
Microbiome Diagnostics for Women's Health
Microbiome Diagnostics for Dental Caries
Overview
Companion Diagnostics In Development
Ibd-210
Ibd-110
Market for Microbiome-Based Diagnostics for Ulcerative Colitis and Crohn's Disease
Overview
Companion Diagnostics In Development
Oricol
Market for Microbiome-Based Diagnostics for Cancer
Overview
Market for Microbiome Diagnostics for Women's Health
Overview
Microbiome-Based Diagnostics In Development
Market for Microbiome-Based Diagnostic for Dental Caries
Chapter 6 Microbiome Intellectual Property, Investments and Collaborations
Intellectual Property
Investments and Collaborations
Overview
Microbiome Patent Segments
Patents By Disease Area
Investments: Overview
Public Sector Investments
Private Sector Investments
Collaborations: Overview
Microbiome Public Databases Overview
Clostridium Difficle Infection
Irritable Bowel Disorders
Diabetes and Obesity
Cancer
Lactose Intolerance
Hyperoxaluria
Recurrent Bacterial Vaginosis and Urinary Tract Infection
Dental Caries
Urea Cycle Disorders
Human Microbiome Initiative
Metahit Initiative
Venture Capital Investments
Initial Public offerings
Industry Collaborations
Vedanta Biosciences/Johnson & Johnson
Seres therapeutics/Nestle Health Science
Enterome Biosciences/Bristol-Meyers Squibb Co. (Bms)
Enterome Biosciences/Abbvie
Enterome Biosciences/Takeda
Synlogic Inc./Abbvie
Second Genome/Johnson & Johnson
Second Genome/Pfizer
Industry/Academic Collaborations
Enterome Biosciences/Mayo Clinic
Janssen Microbiome Institute/Daytwo Ltd. and Weizmann Institute
Vedanta Biosciences/Nyu Langone Medical Center
Seres therapeutics/Massachusetts General Hospital (Mgh)
Seres therapeutics/Mayo Clinic
Seres therapeutics/University of Pennsylvania
Second Genome/the American Gut Project
Second Genome/King's College, London
Whole Biome/Mayo Clinic
American Gut Project Database
Integrative Human Microbiome Project Database
Human Oral Microbiome Database
Chapter 7 Company Profiles
4d Pharma
Avidbiotics Inc.
Aobiome Llc
Axial Biotherapeutics
C3 Jian Inc.
Caelus Health
Da Volterra
Eligo Biosciences
Enterome Biosciences
Evelo Biosciences
Evolve Biosystems
Metabiomics
Microbiome therapeutics
Origin Sciences Ltd.
Osel Inc.
Oxthera
Ritter Pharmaceuticals
Rebiotix Inc.
Second Genome
Seres therapeutics
Symberix
Synlogic Biotics
Synthetic Biologics
Ubiome Inc.
Vedanta Biosciences
Vithera Pharmaceuticals
4d Pharma Pipeline
Avidbiotics Pipeline
Aobiome Pipeline
C3 Jian Pipeline
Caelus Health Pipeline
Da Volterra Pipeline
Enterome Pipeline
Microbiome therapeutics Pipeline
Osel Pipeline
Oxthera Pipeline
Ritter Pharmaceuticals Pipeline
Rebiotix Pipeline
Second Genome Pipeline
Seres therapeutics Pipeline
Symberix Pipeline
Synlogic Pipeline
Synthetic Biologics Pipeline
Vedanta Biosciences Pipeline
Vithera Pharmaceuticals Pipeline
List of Tables
Summary
Table 1 : Summary Table: Global Market For Human Microbiome Based Drugs By Disease Indication, Through 2024
Table 2 : Focus Disease Areas For Microbiome Research
Table 3 : Microbiome Drug Development Approaches
Table 4 : U.S. Prevalence of Cancer, Through 2024
Table 5 : Microbiota Associated With Cancers
Table 6 : Microbiome-Based Drugs In Development For Cancer
Table 7 : U.S. Market Shares of Microbiome-Based Drugs For Cancer, By Company, 2018-2024
Table 8 : U.S. Patient Volumes For Microbiome-Based Drugs For Cancer, By Company, Through 2024
Table 9 : U.S. Market For Microbiome-Based Drugs For Cancer, By Company, Through 2024
Table 10 : Rest of The World Market For Microbiome-Based Drugs For Cancer, By Country/Region, Through 2024
Table 11 : U.S. Prevalence of Obesity, Through 2024
Table 12 : Microbiota Associated With Obesity
Table 13 : Microbiome-Based Drugs In Development For Obesity
Table 14 : U.S. Market Shares of Microbiome-Based Drugs For Obesity, By Company, 2018-2024
Table 15 : U.S. Patient Volumes For Microbiome-Based Drugs For Obesity, By Company, Through2024
Table 16 : U.S. Market For Microbiome-Based Drugs For Obesity, By Company, Through 2024
Table 17 : U.S. Prevalence of Type 2 Diabetes, Through 2024
Table 18 : Microbiota Associated With Type 2 Diabetes
Table 19 : Microbiome-Based Drugs In Development For Type 2 Diabetes
Table 20 : U.S. Market Shares of Microbiome-Based Drugs For Type 2 Diabetes, By Company, 2018-2024
Table 21 : U.S. Patient Volumes For Microbiome-Based Drugs For Type 2 Diabetes, By Company, Through 2024
Table 22 : U.S. Market For Microbiome-Based Drugs For Type 2 Diabetes, By Company, Through 2024
Table 23 : Rest of The World Market For Microbiome-Based Drugs For Type 2 Diabetes, By Country/Region, Through 2024
Table 24 : U.S. Prevalence of Ulcerative Colitis And Crohn's Disease, Through 2024
Table 25 : Microbiome-Based Drugs In Development For Ulcerative Colitis And Crohn's Disease
Table 26 : U.S. Market For Microbiome-Based Drugs For Ulcerative Colitis And Crohn's Disease, Through 2024
Table 27 : Rest of The World Market For Microbiome-Based Drugs For Ulcerative Colitis And Crohn's Disease, Through 2024
Table 28 : U.S. Market Shares of Microbiome-Based Drugs For Ulcerative Colitis, By Company, 2018-2024
Table 29 : U.S. Patient Volumes For Microbiome-Based Drugs For Ulcerative Colitis, By Company, Through 2024
Table 30 : U.S. Market For Microbiome-Based Drugs For Ulcerative Colitis, By Company, Through 2024
Table 31 : Rest of The World Market For Microbiome-Based Drugs For Ulcerative Colitis, By Country/Region, Through 2024
Table 32 : U.S. Market Shares of Microbiome-Based Drugs For Crohn's Disease, By Company, 2018-2024
Table 33 : U.S. Patient Volumes For Microbiome-Based Drugs For Crohn's Disease, By Company, Through 2024
Table 34 : U.S. Market For Microbiome-Based Drugs For Crohn's Disease, By Company, Through 2024
Table 35 : Rest of The World Market For Microbiome-Based Drugs For Crohn's Disease, By Country/Region, Through 2024
Table 36 : U.S. Prevalence of Clostridium Difficle Infection, Through 2024
Table 37 : Microbiome-Based Drugs In Development For Clostridium Difficle Infection
Table 38 : U.S. Market Shares of Microbiome-Based Drugs For Clostridium Difficile Infection, By Company, 2018-2024
Table 39 : U.S. Patient Volumes For Microbiome-Based Drugs For Clostridium Difficile Infection, By Company, Through 2024
Table 40 : U.S. Market For Microbiome-Based Drugs For Clostridium Difficile Infection, By Company, Through 2024
Table 41 : Rest of The World Market For Microbiome-Based Drugs For Clostridium Difficile Infection, By Country/Region, Through 2024
Table 42 : U.S. Prevalence of Lactose Intolerance, Through 2024
Table 43 : Microbiome-Based Drugs In Development For Clostridium Difficle Infection
Table 44 : U.S. Market Shares of Microbiome-Based Drugs For Lactose Intolerance, By Company, 2018-2024
Table 45 : U.S. Patient Volumes For Microbiome-Based Drugs For Lactose Intolerance, By Company, Through 2024
Table 46 : U.S. Market For Microbiome-Based Drugs For Lactose Intolerance, By Company, Through 2024
Table 47 : Rest of The World Market For Microbiome-Based Drugs For Lactose Intolerance, By Country/Region, Through 2024
Table 48 : U.S. Prevalence of Dental Caries, Through 2024
Table 49 : Microbiome-Based Drugs In Development For Clostridium Difficle Infection
Table 50 : U.S. Market Shares of Microbiome-Based Drugs For Dental Caries, By Company, 2018-2024
Table 51 : U.S. Patient Volumes For Microbiome-Based Drugs For Dental Caries, By Company, Through 2024
Table 52 : U.S. Market For Microbiome-Based Drugs For Dental Caries, By Company, Through 2024
Table 53 : Rest of The World Market For Microbiome-Based Drugs For Dental Caries, By Country/Region, Through 2024
Table 54 : U.S. Prevalence of Recurrent Bacterial Vaginosis And Urinary Tract Infection, Through 2024
Table 55 : Microbiome-Based Drugs In Development For Recurrent Bacterial Vaginosis And Urinary Tract Infection
Table 56 : U.S. Market Shares of Microbiome-Based Drugs For Recurrent Bacterial Vaginosis And Urinary Tract Infection, By Company, 2018-2024
Table 57 : U.S. Patient Volumes For Microbiome-Based Drugs For Recurrent Bacterial Vaginosis And Urinary Tract Infection, By Company, Through 2024
Table 58 : U.S. Market For Microbiome-Based Drugs For Recurrent Bacterial Vaginosis And Urinary Tract Infection, By Company, Through 2024
Table 59 : Rest of The World Market For Microbiome-Based Drugs For Recurrent Bacterial Vaginosis And Urinary Tract Infection, By Country/Region, Through 2024
Table 60 : U.S. Prevalence of Skin Diseases, Through 2024
Table 61 : Microbiome-Based Drugs In Development For Skin Diseases
Table 62 : U.S. Market Shares of Microbiome-Based Drugs For Skin Diseases, By Company, 2018-2024
Table 63 : U.S. Patient Volumes For Microbiome-Based Drugs For Skin Diseases, By Company, Through 2024
Table 64 : U.S. Market For Microbiome-Based Drugs For Skin Diseases, By Company, Through 2024
Table 65 : Rest of The World Market For Microbiome-Based Drugs For Skin Diseases, By Country/Region, Through 2024
Table 66 : U.S. Prevalence of Hyperoxaluria, Through 2024
Table 67 : Microbiome-Based Drugs In Development For Skin Diseases
Table 68 : U.S. Market Shares of Microbiome-Based Drugs For Hyperoxaluria, By Company, 2018-2024
Table 69 : U.S. Patient Volumes For Microbiome-Based Drugs For Hyperoxaluria, By Company, Through 2024
Table 70 : U.S. Market For Microbiome-Based Drugs For Hyperoxaluria, By Company, Through 2024
Table 71 : Rest of The World Market For Microbiome-Based Drugs For Hyperoxaluria, By Country/Region, Through 2024
Table 72 : U.S. Prevalence of Urea Cycle Disorder, Through 2024
Table 73 : Microbiome-Based Drugs In Development For Urea Cycle Disorder
Table 74 : U.S. Market Shares of Microbiome-Based Drugs For Urea Cycle Disorder,By Company, 2018-2024
Table 75 : U.S. Patient Volumes For Microbiome-Based Drugs For Urea Cycle Disorder, By Company, Through 2024
Table 76 : U.S. Market For Microbiome-Based Drugs For Urea Cycle Disorder, By Company, Through 2024
Table 77 : U.S. Prevalence of Celiac Disease, Through 2024
Table 78 : Microbiota Associated With Celiac Disease
Table 79 : Microbiome-Based Drugs In Development For Celiac Disease
Table 80 : U.S. Market Shares of Microbiome-Based Drugs For Celiac Disease, By Company, 2018-2024
Table 81 : U.S. Patient Volumes For Microbiome-Based Drugs For Celiac Disease, By Company, Through 2024
Table 82 : U.S. Market For Microbiome-Based Drugs For Celiac Diseases, By Company, Through 2024
Table 83 : U.S. Prevalence of Phenylketonuria, Through 2024
Table 84 : U.S. Market Shares of Microbiome-Based Drugs For Phenylketonuria, By Company, 2018-2024
Table 85 : U.S. Market Shares of Microbiome-Based Drugs For Phenylketonuria, By Company, 2018-2024
Table 86 : U.S. Patient Volumes For Microbiome-Based Drugs For Phenylketonuria, By Company, Through 2024
Table 87 : U.S. Market For Microbiome-Based Drugs For Phenylketonuria, By Company, Through 2024
Table 88 : Rest of The World Market For Microbiome-Based Drugs For Celiac Diseases, By Country/Region, Through 2024
Table 89 : U.S. Prevalence of Non-Alcoholic Steatohepatitis, Through 2024
Table 90 : Microbiome-Based Drugs In Development For Non-Alcoholic Steatohepatitis
Table 91 : U.S. Market Shares of Microbiome-Based Drugs For Non-Alcoholic Steatohepatitis, By Company, 2018-2024
Table 92 : U.S. Patient Volumes For Microbiome-Based Drugs For Non-Alcoholic Steatohepatitis, By Company, Through 2024
Table 93 : U.S. Market For Microbiome-Based Drugs For Non-Alcoholic Steatohepatitis, By Company, Through 2024
Table 94 : Rest of The World Market For Microbiome-Based Drugs For Non-Alcoholic Steatohepatitis, By Country/Region, Through 2024
Table 95 : U.S. Prevalence of Hepatic Encephalopathy, Through 2024
Table 96 : Microbiome-Based Drugs In Development For Hepatic Encephalopathy
Table 97 : U.S. Market Shares of Microbiome-Based Drugs For Hepatic Encephalopathy, By Company, 2018-2024
Table 98 : U.S. Patient Volumes For Microbiome-Based Drugs For Hepatic Encephalopathy, By Company, Through 2024
Table 99 : U.S. Market For Microbiome-Based Drugs For Hepatic Encephalopathy, By Company, Through 2024
Table 100 : Rest of The World Market For Microbiome-Based Drugs For Hepatic Encephalopathy, By Country/Region, Through 2024
Table 101 : Comparison of Microbiome Sequencing Technologies
Table 102 : U.S. Market For Microbiome-Based Diagnostics, By Disease Segment, Through 2024
Table 103 : Rest of The World Market For Microbiome-Based Diagnostics, By Country/Region, Through 2024
Table 104 : U.S. Market Shares of Microbiome-Based Diagnostics For Ulcerative Colitis And Crohn's Disease, 2018-2024
Table 105 : U.S. Assay Volumes For Microbiome-Based Diagnostics For Ulcerative Colitis And Crohn's Disease, Through 2024
Table 106 : U.S. Market For Microbiome-Based Diagnostics For Ulcerative Colitis And Crohn's Disease, Through 2024
Table 107 : U.S. Prevalence of Microbiome-Based Diagnostics For Colorectal Cancer, Through 2024
Table 108 : U.S. Market Shares of Microbiome-Based Diagnostics For Colorectal Cancer, By Company, 2018-2024
Table 109 : U.S. Assay Volumes For Microbiome-Based Diagnostics For Colorectal Cancer, Through 2024
Table 110 : U.S. Market For Microbiome-Based Diagnostics For Colorectal Cancer, Through 2024
Table 111 : U.S. Prevalence of Microbiome-Based Diagnostics For Women's Health, Through 2024
Table 112 : U.S. Market Shares of Microbiome-Based Diagnostics For Women's Health, By Company, 2018-2024
Table 113 : U.S. Assay Volumes For Microbiome-Based Diagnostics For Women's Health, Through 2024
Table 114 : U.S. Market For Microbiome-Based Diagnostics For Women's Health, Through 2024
Table 115 : U.S. Market Shares of Microbiome-Based Diagnostics For Dental Caries, By Company, 2018-2024
Table 116 : U.S. Assay Volumes For Microbiome-Based Diagnostics For Dental Caries, Through 2024
Table 117 : U.S. Market For Microbiome-Based Diagnostics For Dental Caries, By Company Through 2024
Table 118 : U.S. Patents And Patent Applications on Microbiome-Based Drugs For C. Difficle Infection
Table 119 : U.S. Patents And Patent Applications on Microbiome-Based Drugs For Irritable Bowel Syndrome
Table 120 : U.S. Patents And Patent Applications on Microbiome-Based Drugs For Diabetes And Obesity
Table 121 : U.S. Patents And Patent Applications on Microbiome-Based Drugs For Cancer
Table 122 : U.S. Patents And Patent Applications on Microbiome-Based Drugs For Lactose Intolerance
Table 123 : U.S. Patents And Patent Applications on Microbiome-Based Drugs For Hyperxaluria
Table 124 : U.S. Patents And Patent Applications on Microbiome-Based Drugs For Recurrent Bacterial Vaginosis And Urniary Tract Infection
Table 125 : U.S. Patents And Patent Applications on Microbiome-Based Drugs For Dental Caries
Table 126 : U.S. Patents And Patent Applications on Microbiome-Based Drugs For Urea Cycle Disorders
Table 127 : Venture Capital Investments In Microbiome Start-Ups
Table 128 : Initial Public offerings By Microbiome-Based Companies
Table 129 : Industry Collaborations In Microbiome-Based Companies
Table 130 : 4d Pharma Pipeline
Table 131 : Avidbiotics Pipeline
Table 132 : Aobiome Pipeline
Table 133 : C3 Jian Pipeline
Table 134 : Caelus Pipeline
Table 135 : Da Volterra Pipeline
Table 136 : Enterome Pipeline
Table 137 : Microbiome Therapeutics Pipeline
Table 138 : Osel Pipeline
Table 139 : Oxthera Pipeline
Table 140 : Oxthera Pipeline
Table 141 : Rebiotix Pipeline
Table 142 : Second Genome Pipeline
Table 143 : Seres Therapeutics Pipeline
Table 144 : Synlogic Pipeline
Table 145 : Synthetic Biologics Pipeline
Table 146 : Vedanta Biosciences Pipeline
Table 147 : Vithera Pharmaceuticals Pipeline
List of Figures
Figure 1 : Summary Figure A: Global Market For Human Microbiome Based Drugs And Diagnostics, 2018-2024
Figure 2 : Summary Figure B: Global Market For Human Microbiome Based Drugs By Region, 2018-2024
Figure 3 : Summary Figure C: Global Market For Human Microbiome Based Diagnostics By Region, 2018-2024
Figure 4 : Human Microbiome Based Drugs, Pipeline Projects, 2016
Figure 5 : Microbes Involved In Healthy Facial Skin
Figure 6 : Number of Patents Granted For Worldwide Microbiome-Based Drugs, 2002-2016
Global Cytokine Inhibitor Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 85
The global Cytokine Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
The development prospects of cytokine inhibitors are very broad, and these drugs have many medical applications and researches. Cytokine inhibitors can reduce The activity of cytokines, thereby inhibiting their role in immune responses and reducing The activation of immune cells and The occurrence o......
Global Microbial Growth Media Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 93
Microbial Growth Media is a nutrient component required by microorganisms, containing a variety of trace elements and trace elements, such as copper, iron, zinc, cobalt, manganese, etc.
The global Microbial Growth Media market was valued at US$ 8007 million in 2023 and is anticipated to reach US$ 11530 million by 2030, witnessing a CAGR of 5.3% during The forecast period 2024-2030.
The market for microbial growth media is essential in microbiology and biotechnology rese......
Global Protein Biochip Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 92
Protein Biochip is a small Protein array used to quickly detect a large number of unknown proteins. It works in a similar way to a DNA chip. First, a large number of known proteins (such as monoclonal antibodies) are placed on a small substrate and then exposed to and reacted with The unknown protein sample. Due to The specific binding between The antigen and The antibody, it can finally be detected by means of laser.
The global Protein Biochip market was valued at US$ 145 million i......
Global Isothermal Nucleic Acid Amplification Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 103
Isothermal nucleic acid amplification is referred to isothermal nucleic acid amplification technology. And in this report, we get The statistics on reagents used in isothermal nucleic acid amplification technology. Nucleic acid isothermal amplification is a newer technique that amplifies DNA or RNA specific fragment from few copies to billion-fold copies under a one temperature condition, unlike PCR amplification that needs at least 30-35 thermal cycles to accomplish The reaction.
T......
Global Microfluidics Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 134
According to our LPI (LP Information) latest study, the global Microfluidics market size was valued at US$ 3118.7 million in 2023. With growing demand in downstream market, the Microfluidics is forecast to a readjusted size of US$ 7707.1 million by 2030 with a CAGR of 13.8% during review period.
The research report highlights the growth potential of the global Microfluidics market. Microfluidics are expected to show stable growth in the future market. However, product differentiation, re......
Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 122
According to our LPI (LP Information) latest study, the global Isothermal Nucleic Acid Amplification Technology (INAAT) market size was valued at US$ 6141.3 million in 2023. With growing demand in downstream market, the Isothermal Nucleic Acid Amplification Technology (INAAT) is forecast to a readjusted size of US$ 11250 million by 2030 with a CAGR of 9.0% during review period.
The research report highlights the growth potential of the global Isothermal Nucleic Acid Amplification Technol......
Global Cytokines Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 119
According to our LPI (LP Information) latest study, the global Cytokines market size was valued at US$ 203730 million in 2023. With growing demand in downstream market, the Cytokines is forecast to a readjusted size of US$ 611910 million by 2030 with a CAGR of 17.0% during review period.
The research report highlights the growth potential of the global Cytokines market. Cytokines are expected to show stable growth in the future market. However, product differentiation, reducing costs, an......
Global Western Blot Imagers Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 94
According to our LPI (LP Information) latest study, the global Western Blot Imagers market size was valued at US$ 406 million in 2023. With growing demand in downstream market, the Western Blot Imagers is forecast to a readjusted size of US$ 578.4 million by 2030 with a CAGR of 5.2% during review period.
The research report highlights the growth potential of the global Western Blot Imagers market. Western Blot Imagers are expected to show stable growth in the future market. However, prod......
Global Procalcitonin Antibody Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 125
According to our LPI (LP Information) latest study, the global Procalcitonin Antibody market size was valued at US$ million in 2023. With growing demand in downstream market, the Procalcitonin Antibody is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Procalcitonin Antibody market. Procalcitonin Antibody are expected to show stable growth in the future market. However, product di......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
